Results 1 to 10 of about 17,014 (180)

SOM3355: a unique pharmacological profile combining VMAT1 inhibition, VMAT2-mediated dopamine modulation, and β1-adrenergic antagonism for the treatment of movement and neuropsychiatric disorders [PDF]

Frontiers in Pharmacology
Unmet needs in hyperkinetic movement disorders (HMDs) within neuropsychiatric conditions include better treatments for HMDs in complex disorders like Huntington’s disease (HD), Tourette syndrome and psychiatric comorbidities like tardive dyskinesia.
Emily S. Turilli-Ghisolfi, Svein Isungset Støve, Svein Isungset Støve, Oscar Huertas, Trond-André Kråkenes, Trond-André Kråkenes, Knut Teigen, Knut Teigen, Silvia Panigone, Rossella Medori   +9 more
doaj   +2 more sources

Non-Selective PDE4 Inhibition Induces a Rapid and Transient Decrease of Serum Potassium in Mice

Biology, 2022
The analysis of blood samples from mice treated with the PDE4 inhibitor Roflumilast revealed an unexpected reduction in serum potassium levels, while sodium and chloride levels were unaffected.
Abigail Boyd, Peter Lochmaier, Daniel Irelan, Edward Fiedler, Ji Young Lee, Brian Fouty, Lina Abou Saleh, Wito Richter   +7 more
doaj   +1 more source

Identification of factors associated with the efficacy of atomoxetine in adult attention‐deficit/hyperactivity disorder

Neuropsychopharmacology Reports, 2022
Aim Atomoxetine (ATX) is a non‐central stimulant and a standard treatment for adult attention‐deficit/hyperactivity disorder (ADHD). The long‐term efficacy of Atomoxetine is about 40% at 6 months.
Tsutomu Nagai, Tatsuya Kurihara, Hiroaki Koya, Yukako Nakano, Satoru Sugisawa, Takehiko Sambe, Keiko Kishimoto, Mari Kogo, Haruhisa Ota, Akira Iwanami, Naoki Uchida   +10 more
doaj   +1 more source

Regulatory effect of connexin 43 on basal Ca2+ signaling in rat ventricular myocytes. [PDF]

PLoS ONE, 2012
BACKGROUND: It has been found that gap junction-associated intracellular Ca(2+) [Ca(2+)](i) disturbance contributes to the arrhythmogenesis and hyperconstriction in diseased heart.
Chen Li, Qingli Meng, Xinfeng Yu, Xian Jing, Pingxiang Xu, Dali Luo   +5 more
doaj   +1 more source

A machine learning and network framework to discover new indications for small molecules.

PLoS Computational Biology, 2020
Drug repurposing, identifying novel indications for drugs, bypasses common drug development pitfalls to ultimately deliver therapies to patients faster. However, most repurposing discoveries have been led by anecdotal observations (e.g.
Coryandar Gilvary, Jamal Elkhader, Neel Madhukar, Claire Henchcliffe, Marcus D Goncalves, Olivier Elemento   +5 more
doaj   +1 more source

Management of Urinary Incontinence Following Radical Prostatectomy: Challenges and Solutions

Therapeutics and Clinical Risk Management, 2023
Pietro Castellan,1 Simone Ferretti,2 Giulio Litterio,2 Michele Marchioni,1,2 Luigi Schips1,2 1Department of Urology, ASL02 Abruzzo, Chieti, Italy; 2Department of Medical, Oral and Biotechnological Sciences, G.
Castellan P, Ferretti S, Litterio G, Marchioni M, Schips L   +4 more
doaj  

Identification of Brimonidine as a Novel Substrate of Organic Cation Transporters OCT2 and MATE1 Expressed in Human Eye. [PDF]

Invest Ophthalmol Vis Sci
Kölz C, Neul C, Hofmann U, Dressler JC, Süsskind D, Wissinger B, Schwab M, Nies AT.   +7 more
europepmc   +1 more source

Iron Matters: Comparative Impact of Beta-Adrenergic Stimulation and Iron Chelation on Cardiac Iron Metabolism and Mitochondrial Function. [PDF]

Biomolecules
Francesch-Manzano J, Tajes M, Ramos-Polo R, Enjuanes C, Ras-Jiménez MDM, Cosa AE, Marinova K, Enrich-Soria C, Moliner P, Lorenzo-Esteller L, José-Bazán N, Comín-Colet J.   +11 more
europepmc   +1 more source

Evaluation of the Relationship between Vesicular Monoamine Transporter 2 (VMAT2) Inhibition and Neurologic Adverse Events in Approved Drugs. [PDF]

ACS Pharmacol Transl Sci
Racz R, Kozell LB, Eshleman AJ, Bloom SH, Wolfrum KM, Schmachtenberg JL, Swanson TL, Ngai J, Schutzer WE, Janowsky A, Abbas AI, Stavitskaya L.   +11 more
europepmc   +1 more source

Evolving strategies in obstructive hypertrophic cardiomyopathy: myosin inhibitors as monotherapy compared with beta-blockers. [PDF]

Heart Fail Rev
Grupper A, Sverdlov AL, Cheema BS, Nasrollahizadeh A, Hosseini K.   +4 more
europepmc   +1 more source